EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY 4.0

The evolving role of placebo in non-inferiority trials: A scoping review

Spencer Cho, Shaheer Nadeem, Valentina Ly, Iman Alhafez, Tim Ramsay, Pil Joo iD

Clinical Trials · 2026-08 · 23 (4) · 439-446

DOI: 10.1177/17407745261430850 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Clinical Trials, online erschienen am 06.04.2026. Verfasst von Spencer Cho und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada. Hauptthemen laut MEDLINE: Equivalence Trials as Topic, Research Design, Randomized Controlled Trials as Topic. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Ottawa Hospital Department of Family Practice.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non-inferiority trials can be used for efficacy endpoints or safety endpoints, with indirect and direct comparison to placebo. A less common application of this design involves using placebo as the proposed intervention to challenge standard practices that lack evidence of efficacy. However, the methodology of using a placebo in a non-inferiority trial is poorly described in the literature. We performed a scoping review to map how placebo is utilized in randomized controlled trials with a non-inferiority design, with particular attention to studies positioning placebo as a proposed alternative to existing, but unproven, interventions.

Methods

We conducted a scoping review of randomized controlled trials using non-inferiority designs with a placebo arm, searching six databases without date or language restrictions. Eligible studies were primary randomized controlled trials with at least one placebo arm evaluated under a non-inferiority hypothesis. Data extraction focused on study characteristics, design elements, rationale for non-inferiority design and margin, and analytical practices.

Results

Of 6897 studies screened, 94 met inclusion criteria. Three primary study types were identified: safety (63%), deprescription (20%), and shorter-course (13%) trials. There has been increased use of deprescription and shorter-course studies since 2017. One-third (35%) hypothesized that placebo was non-inferior to active treatment, predominantly in deprescription and shorter-course trials focused on antibiotic use. Most studies (94%) applied non-inferiority analysis to primary outcomes, yet only 22% provided a rationale for non-inferiority design, and despite 96% prespecifying non-inferiority margin, only 41% justified the margin. While 71% used intention-to-treat analysis, only 53% conducted per-protocol analysis. Graphical representation of non-inferiority margins and confidence intervals was reported in 23% of studies.

Conclusion

Placebo is increasingly used in non-inferiority trials aimed at evaluating the necessity of standard interventions, including safety, deprescription, and shorter-course designs. However, many trials lack critical methodological transparency. Future studies should clearly justify non-inferiority designs and margins, use both intention-to-treat and per-protocol analyses, and adhere to the Consolidated Standards of Reporting Trials reporting guidelines to enhance interpretability and rigor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Equivalence Trials as TopicResearch DesignRandomized Controlled Trials as TopicHumansPlacebosPlacebo Effect

Stichwörter der Autor:innen

Non-inferiorityplaceborandomized controlled trialscoping review

Substanzen

Placebos

Autor:innen und Institutionen

  • Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
  • Health Sciences Library, University of Ottawa, Ottawa, ON, Canada.
  • Department of Family Medicine, University of Ottawa, Ottawa, ON, Canada.
  • Ottawa Hospital Research Institute, Ottawa, ON, Canada.

ORCID-Profile: Pil Joo

Förderung

  • The Ottawa Hospital Department of Family Practice

Zitieren

APA

Cho, S., Nadeem, S., Ly, V., Alhafez, I., Ramsay, T., & Joo, P. (2026). The evolving role of placebo in non-inferiority trials: A scoping review. Clinical Trials, 23(4), 439-446. https://doi.org/10.1177/17407745261430850

Vancouver

Cho S, Nadeem S, Ly V, Alhafez I, Ramsay T, Joo P. The evolving role of placebo in non-inferiority trials: A scoping review. Clinical Trials. 2026;23(4):439-446. doi:10.1177/17407745261430850

BibTeX
@article{Cho2026,
  author = {Cho, Spencer and Nadeem, Shaheer and Ly, Valentina and Alhafez, Iman and Ramsay, Tim and Joo, Pil},
  title = {The evolving role of placebo in non-inferiority trials: A scoping review},
  journal = {Clinical Trials},
  year = {2026},
  volume = {23},
  number = {4},
  pages = {439--446},
  doi = {10.1177/17407745261430850}
}
Kostenlos starten →